H.C. Wainwright lowered the firm’s price target on Panbela Therapeutics to $5 from $16 and keeps a Buy rating on the shares following the Q4 results. The analyst cites the 1-for-20 reverse split in January for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBLA:
- Panbela Therapeutics files to sell 255.6K shares of common stock for holders
- Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
- Is PBLA a Buy, Before Earnings?
- Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
- Panbela Therapeutics Regains Compliance with Nasdaq Standards
